WHO To Decide On EUL Of Ocugen-Partnered COVID-19 Vaccine Today

An expert panel of the World Health Organization (WHO) will decide on the emergency use listing (EUL) authorization of Covaxin today.
Covaxin is India's indigenously-developed COVID-19 vaccine, in collaboration with Ocugen Inc OCGN.
Related: Ocugen-Partnered Covaxin's WHO Clearance Delayed Further Over Queries: Sources.
According to SEC filing, Bharat Biotech International Limited will exclusively manufacture and supply Ocugen with its requirements of Covaxin clinical trial materials and manufacture & supply Covaxin drug product components and finished drug product after regulatory approval.
Additionally, Ocugen amended the Co-Development and Commercialization Agreement with CanSino Biologics Inc and added Ocugen's OCU410 to the existing collaboration.
OCU410 utilizes the nuclear receptor genes RAR-related orphan receptor A for dry age-related macular degeneration.
CanSino will be responsible for the chemistry, manufacturing, and controls development and manufacture of clinical supplies of OCU410.
CanSino will have an exclusive option to obtain a non-exclusive license to manufacture OCU410 commercially.
CanSino will have an exclusive license to develop, manufacture, and commercialize OCU410 products in and for China, Hong Kong, Macau, and Taiwan.
Ocugen will maintain exclusive development, manufacturing, and commercialization rights for OCU410 products outside the CanSino Territory.
Price Action: OCGN stock is up 6.07% at $7.16 during the premarket session on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga